Expand PPH Menu
PPH MENU

PPH ETF Profile


Family: Van Eck Associates Corporation
Name: VanEck Pharmaceutical ETF
Inception Date: 20-Dec-2011
Termination Date:
Investment Objective: The Market Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index. The Index is a rules-based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded pharmaceutical companies.
Prospectus
Top 10 Holdings
Eli Lilly & Co LLY 12.3655%
Novo Nordisk A/S NVO 8.3989%
Johnson & Johnson JNJ 6.3464%
Abbvie Inc ABBV 5.8970%
Bristol-Myers Squibb Co BMY 5.7391%
Mckesson Corp MCK 5.5612%
Merck & Co Inc MRK 4.8411%
Cencora Inc COR 4.8324%
Novartis Ag NVS 4.7052%
Haleon Plc HLN 4.6110%
Top 10 Holdings Weight: 63.3%
Number of Holdings: 27
Shares Outstanding: 6,788,138
Total Net Assets: 601,904,200
NAV: 88.65
Net Expense Ratio: 0.36%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country:
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry: Pharmaceuticals
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: Broad Market / Multi-Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged: No
US or Ex-US: Global